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A Survey of Current Attitudes of British and Irish Vascular Surgeons to 
Venous Sclerotherapy 
R. B. Galland ~1, T. R. Magee 1 and M. H. Lewis 
Departments of Surgery, Reading ~ and East Glamorgan General Hospital, Mid Glamorgan, U.K. 
Aim: To determine current practice amongst vascular surgeons regarding venous clerotherapy. 
Method: A postal questionnaire was sent to 350 members of the Vascular Surgical Society of Great Britain and Ireland. 
Results: There were 218 replies (62%). Forty surgeons (18.3%) never injected varicose veins (VV) although six injected 
venous flares. Most surgeons (n= 168, 77.1%) reserved sclerotherapy for residual VV postoperatively. Primary varicose 
veins without proximal incompetence were injected by 152 (69.7%) and recurrent VV without proximal incompetence 
by 141 (64.7%). Sixteen surgeons only injected residual postoperative VV. Few surgeons injected VV in the presence of 
proximal incompetence. 
Where specified, 46% of respondents were injecting fewer VVs than in previous years. Only 5% were injecting more. 
By contrast, 44% were injecting more venous flares than previously (p<O.O01). Eight different sclerosants were used, 
the commonest being STD (146 surgeons) and Sclerovein (33). The median number of patients treated with sclerotherapy 
was 11-50 per year compared with 51-150 per year who were operated upon. The median time advised for compression 
was 2 weeks (range - a few minutes - 2 months). Treatment was repeated at a median 0]:4 weeks (0-6 months). Thirty- 
two surgeons obtained written consent. All but eight respondents discussed potential complications, the commonest being 
staining and ulceration. Forty-six surgeons had patients who had experienced serious complications, the commonest being 
ulceration. There was one reported eath from a pulmonany embolus. 
Conclusion: Sclerotherapy is being used less frequently for VV. Most surgeons use it for residual VV and for those 
without proximal incompetence. 
Introduction 
Sclerotherapy has been advocated for the treatment of 
varicose veins (VV) for over 30 years. ~ Despite this, its 
role, particularly in relation to other types of treatment, 
has yet to be fully established. Sclerotherapy has been 
suggested as an alternative to surgical treatment or to 
be used in combination with it. In the latter area it 
has been used at the time of operation 2 or on an out- 
patient basis following saphenofemoraP or sapheno- 
popliteal ligation. Several different sclerosants are 
available and different techniques have been ad- 
vocated for their usage. Tournay's technique consists 
of sclerosing the highest reflux point and moving 
distally. Compression is advocated for only selective 
cases and for a short time. 4 Sigg advocates a technique 
which requires sclerotherapy of distal varicose veins 
followed by dealing with more proximal varices. 5 In 
Fagan's technique sclerotherapy is carried out on per- 
forators moving from the most distal to most prox- 
imal. 1 In the latter two techniques compression is 
* Please address all correspondence to: R. Galland, Royal Berkshire 
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A postal questionnaire was sent to members of the 
Vascular Surgical Society of Great Britain and Ireland 
(VSS). 
Questions were directed towards indications for 
sclerotherapy, whether written consent was obtained 
and whether potential complications were discussed. 
Details of serious complications encountered by sur- 
geons were sought. The numbers of episodes of sclero- 
pathy and operations per year were noted along with 
the grade of those undertaking sclerotherapy in their 
strongly advised. Ultrasound-guided sclerotherapy 
has recently been advocated. 6 
A recent consensus tatement on varicose veins 
sclerotherapy emphasised the difficulty in defining 
the true efficacy of the technique and under what 
circumstances it should be used. 7
The aim of this study was to determine the current 
practice and attitude towards venous sclerotherapy of
British and Irish vascular surgeons. 
Methods 
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Table 1. Indications for sclerotherapy and sclerosants used. 
Use of sclerotherapy n (%) 
Never 40 (18.3) 
Primary with proximal incompetence 10 (4.6) 
without proximal incompetence 152 (69.7) 
At operation 9 (4.1) 
Residual after operation 168 (77.1) 
Recurrent with proximal incompetence 
without proximal incompetence 
10 
141 
Sclerotherapy carried out by 
Consultant 111 
Specialist registrar 88 
BST 32 
Staff grade/clinical ssistant/GP assistant 35 
Nurse 2 
Sclerosant used 
Sodium tetradecyl sulphate 146 
Sclerovein 33 
Aethoxysklerol 9 
Ethanolamine 8 
Scleremo 7 
Hypertonic saline 4 
Salicylate 1 
EDTA 1 
Time of compression 
a) VV 
b) venous flares 
Interval at which treatment repeated 
a) VV 
b) venous flares 
Median 2 weeks 
(10 rain-8 weeks) 
Median 4 days 
(a few rain-6 weeks) 
Median 4 weeks 
(0-6 months) 
Median 4 weeks 
(0-6 months) 
(4.6) 
(64.7) 
Comments 
6 inject flares 
16 use scleropathy for this 
indication only 
Fibro-vein (R) 
Polidocanol 
Chrome alum, glycerol 
department. The length and type of compression and 
interval between repeat treatments were noted along 
with the sclerosant used both for varicose veins and 
venous flares. Finally surgeons were asked to comment 
as to whether they were doing more, the same or less 
sclerotherapy than in previous years. 
Results 
Questionnaires were sent to 350 members of the VSS. 
Replies were received from 218 (62%). Forty re- 
spondents claimed never to use sclerotherapy (Table 
1). Of the remainder, most used sclerotherapy for 
pr imary or recurrent varicose veins without overt 
saphenofemoral  or saphenopopliteal incompetence. 
The main use was for residual veins following oper- 
ation. The median number  of patients treated with 
sclerotherapy was 11-50 per year, compared with 51- 
150 who were operated upon (Fig. 1). 
Sclerotherapy was mostly given by consultants or 
specialist registrars. Eight different sclerosants were 
used, the commonest being sodium tetradecyl sul- 
phate. The median time for compression following 
sclerotherapy for varicose veins was two weeks 
whereas that following treatment of venous flares 
was only four days. The median interval between 
treatments for both venous disorders was 4 weeks. 
Only 32 respondents (17.4%) obtained written con- 
sent, although 178 (96.7%) discussed potential com- 
plications: the main ones mentioned being skin 
staining and ulceration (Table 2). Written information 
sheets were provided by four surgeons. Serious com- 
plications had been encountered by 46 surgeons 
(25.5%), ulceration being the commonest. Only three 
surgeons had experience of patients having ana- 
phylactic reactions. One surgeon reported a death due 
to pulmonary embolus. 
A specialised varicose vein clinic was available to 
78 respondents (35.8%), six of whom did not carry out 
sclerotherapy. 
Significantly more surgeons are increasing their use 
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Fig. 1. Number of episodes of sclerotherapy oroperations per year (where specified). 
Table 2. Consent and complications (n = 178 + 6 respondents who 
injected venous flares only). 
Written consent obtained 
Potential complications discussed 
Staining 
Necrosis/ulceration 
Phlebitis 
Recurrence 
Pain 
DVT 
Lumps 
Allergic reaction 
Serious complications encountered 
Ulceration 
Staining 
DVT/pulmonary embolus 
Anaphylaxis 
Staphlococcal septicaemia 
Severe pain 
60 
50 32 
178 (96.7%) 
115 • 40 
101 
43 ~ 30 
37 
32 
19 ~ 20 
lO 
9 ;~ lO 
46 (25.5%) 0 
19 
8 
4 (1 fatal PE) 
3 
1 
1 
of sclerotherapy for venous flares compared with those 
increasing their use of sclerotherapy for varicose veins 
(Chi-squared 58, d.f. 1, p<0.001, 95% CI 0.28-0.49), Fig. 
2. Similarly fewer surgeons are using sclerotherapy 
for VV than flares (chi-squared 14, d.f. 1, p<0.001, 95% 
CI -0 .32- -0 .12) .  Although approximately 50% of 
surgeons have not changed their practice in relation 
to VV sclerotherapy significantly more have changed 
their practice regarding treatment of flares (chi- 
squared 5.7, d.f. 1, p<0.025, 95% CI -0 .28- -0 .03) .  
A total of 54 respondents referred patients with 
venous flares to other departments. The majority re- 
ferred to dermatologists (37) or plastic surgeons (14) 
for microsclerotherapy or laser treatment. 
- -  I 
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Figure 2. Changing practice for sclerotherapy of VV ([]) or venous 
flares ([~). 
Discussion 
Patients with varicose veins make up a significant 
proport ion of surgical waiting lists, s Even though most 
operations can be carried out on a day case basis, 9they 
account for a considerable amount of NHS resources. 
Furthermore, between 1975 and 1987 there was almost 
a doubling of hospital admissions for varicose vein 
treatment. 1° Despite this our survey shows that fewer 
members of the VSS are utilising sclerotherapy for 
varicose veins than in previous years. Far more patients 
are being offered operation. Some units have ex- 
perience of many thousands of episodes of sclero- 
therapy with acceptable arly results. 5However,  most 
VV are referred to surgeons and it is clear that pr imary 
sclerotherapy will therefore be offered to few patients. 
In a recent survey of 229 newly referred patients with 
varicose veins, operation was offered to 49%, but 
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sclerotherapy to only 8.7%. II Our results also show 
that approximately half of those surgeons who spe- 
cified stated that they were carrying out less sclero- 
therapy for VV than in previous years. This 
presumably reflects dissatisfaction with the results 
and complications of sclerotherapy compared with 
operation. 
Results of sclerotherapy vary from study-to-study 
depending upon the type of veins injected. Results are 
"poor" for the treatment of long saphenous varicose 
veins and "fair" for treating non-saphenous varicose 
veins and perforators. 7 A comparison of stripping or 
sclerotherapy combined with saphenofemoral ligation 
showed significantly better results with the former. 3
Few respondents in our series were prepared to use 
sclerotherapy in the presence of proximal in- 
competence. The main indication for its use being 
residual varices postoperatively. 
The present study shows that 178 (96.7%) of re- 
spondents discussed potential complications with 
patients prior to sclerotherapy. Skin discolouration 
was the commonest problem mentioned followed by 
ulceration. Serious complications have been ex- 
perienced by 46 surgeons (25.5%). Ulceration or skin 
necrosis was the commonest. Four surgeons had 
patients who suffered from thrombotic omplications, 
one of whom died of a pulmonary embolus. Risk of 
complication depends on such factors as the type, 
volume and strength of sclerosant injected. Ulceration 
has been described in up to 3% of cases, t2 However, 
a recent large series describes this problem in less than 
1% of patients) 3 The commonest problem likely to 
result in litigation involves extravasation of sclerosant 
following sclerotherapy. 14 Estimates uggest hat skin 
staining occurs in about 8% and flare formation in 4% 
of cases following sclerotherapy. 15 
There was considerable variability in the length of 
time compression was advised after VV sclerotherapy, 
ranging from a few minutes to 8 weeks. The median 
time which compression was advised for venous flares 
was 4 days compared with 2 weeks for VV. It has been 
suggested that prolonged bandaging is not required 
after sclerotherapy. ~6 Furthermore support stockings 
may be as effective and more comfortable than band- 
ages. ~7 
The need for training programmes in sclerotherapy 
has recently beem emphasised. 7 Only 71 surgeons 
who carried out sclerotherapy in our survey have a 
specialised varicose vein clinic. Such clinics would be 
required for training to be effective. Most sclerotherapy 
was undertaken by consultant or specialist registrars. 
This survey shows that sclerotherapy is being used 
less often than operation for the treatment of VV. 
Most surgeons use sclerotherapy for residual VV after 
operation and for those without proximal in- 
competence. Interest in sclerotherapy for VV seems to 
be declining whereas that for venous flares is in- 
creasing. 
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